<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037165</url>
  </required_header>
  <id_info>
    <org_study_id>1320.3</org_study_id>
    <secondary_id>2012-005691-33</secondary_id>
    <nct_id>NCT02037165</nct_id>
  </id_info>
  <brief_title>Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers</brief_title>
  <official_title>Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      -  To investigate the influence of different doses of BI 1026706 on the primary endpoint
           (PtP-amplitude LEP in UV skin) compared to placebo.

        -  The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment.

        -  Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin
           treatment

        -  Exploration of the pharmacokinetics of BI 1026706

        -  Exploration of safety and tolerability of BI 1026706
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Peak-to-Peak (PtP) N2/P2-component amplitude of Laser (somatosensory/radiant heat) evoked potentials (LEP) [µV] in UVB-irradiated skin</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Peak-to-Peak (PtP) N2/P2-component amplitude of (LEP) [µV] in capsaicin-irritated skin</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single &quot;peripheral&quot; (N2) component amplitudes [µV] - measured in both treated skin types</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single &quot;central&quot; (P2) component amplitudes [µV] - measured in both treated skin types</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electronic Visual Analogue Scale (100mm VAS &quot;Post Laser Pain&quot; scales) - measured in the two different skin types</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted needle (pain) threshold (WNT) the secondary capsaicin flare area</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Treatment 1: BI 1026706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Treatment 2: BI 1026706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1026706 and placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Treatment 1: BI 1026706</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo to BI 1026706 PfOS and placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Treatment 2: Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Treatment 3: Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Test Treatment 2: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo oral solution</description>
    <arm_group_label>Reference Treatment 2: Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>Pregabalin hard capsule</description>
    <arm_group_label>Reference Treatment 3: Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo oral solution</description>
    <arm_group_label>Test Treatment 1: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo oral solution</description>
    <arm_group_label>Reference Treatment 3: Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Test Treatment 1: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Reference Treatment 1: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <description>BI 1026706 oral solution</description>
    <arm_group_label>Test Treatment 1: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1026706</intervention_name>
    <description>BI 1026706 oral solution</description>
    <arm_group_label>Test Treatment 2: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1026706</intervention_name>
    <description>Placebo oral solution</description>
    <arm_group_label>Reference Treatment 1: BI 1026706</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib hard capsule</description>
    <arm_group_label>Reference Treatment 2: Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the investigator's assessment, as based on the following
             criteria: a complete medical history including a physical examination, vital signs
             (Blood Pressure, Pulse Rate), 12-lead electrocardiogram, and clinical laboratory

          2. Age 18 to 55 years (incl.)

          3. BMI (Body Mass Index) 18.5 to 29.9 kg/m2 (incl.)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          1. Any finding in the medical examination (including Blood Pressure, Pulse Rate or
             Electrocardiogram) deviating from normal and judged clinically relevant by the
             investigator

          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic
             blood pressure greater than 90 mm Hg

          3. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          4. Any evidence of a concomitant disease judged clinically relevant by the investigator

          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          6. Surgery of the gastrointestinal tract that could interfere with kinetics of the study
             drug(s)

          7. Diseases of the central nervous system (such as epilepsy), other neurological
             disorders or psychiatric disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1320.3.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dornach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

